Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michael Gibson

Showing results (61-70 of 680) with videos related to

Pageof 68
Sort By:
Expert Opinion on Investigational Drugs|November 1, 2018
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarctionDavide Capodanno, Roxana Mehran, C Michael Gibson, et al.
American Heart Journal|June 17, 2006
Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarctionDuane S Pinto, Matthew Southard, Lauren Ciaglo, et al.
European Heart Journal|June 12, 2004
Time is muscle in primary PCI: the strength of the evidence growsC Michael Gibson, James A de Lemos, Elliott M Antman, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 5, 2023
The Relationship Between the Age of First Acute Coronary Syndrome Episode and Internal MigrationDeniz Demirci, Duygu Ersan Demirci, Gerald Chi, et al.
American Heart Journal|July 12, 2011
Association of initial thrombolysis in myocardial infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a National Registry of Myocardial Infarction-5 (NRMI-5) analysisJinhui Wu, Yuri B Pride, Paul D Frederick, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 2, 2026
Cardiovascular Adverse Effects of Common Non-Oncologic Medications: From Mechanisms to Clinical ManagementM Cecilia Bahit, Pilar Agudo-Quilez, Jose Zamorano, et al.
Pharmacoeconomics - Open|June 23, 2025
Cost-Effectiveness of the CADScor System in Low-Risk Patients Presenting to the Emergency Department with Chest PainSuzanne J Baron, Serge Korjian, C Michael Gibson, et al.
Biology Methods & Protocols|May 21, 2026
Weight trajectories after last tirzepatide or semaglutide prescription across a federated health networkKarthik Murugadoss, Gowtham Varma, A J Venkatakrishnan, et al.
The American Journal of Cardiology|April 26, 2003
Meta-analysis of corticosteroid treatment in acute myocardial infarctionGregory R Giugliano, Robert P Giugliano, C Michael Gibson, et al.
American Heart Journal|April 23, 2005
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trialMarc S Sabatine, Carolyn H McCabe, C Michael Gibson, et al.
Pageof 68

Showing results (61-70 of 680) with videos related to

Sort By:
Pageof 68
Expert Opinion on Investigational Drugs|November 1, 2018
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarctionDavide Capodanno, Roxana Mehran, C Michael Gibson, et al.
American Heart Journal|June 17, 2006
Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarctionDuane S Pinto, Matthew Southard, Lauren Ciaglo, et al.
European Heart Journal|June 12, 2004
Time is muscle in primary PCI: the strength of the evidence growsC Michael Gibson, James A de Lemos, Elliott M Antman, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 5, 2023
The Relationship Between the Age of First Acute Coronary Syndrome Episode and Internal MigrationDeniz Demirci, Duygu Ersan Demirci, Gerald Chi, et al.
American Heart Journal|July 12, 2011
Association of initial thrombolysis in myocardial infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a National Registry of Myocardial Infarction-5 (NRMI-5) analysisJinhui Wu, Yuri B Pride, Paul D Frederick, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 2, 2026
Cardiovascular Adverse Effects of Common Non-Oncologic Medications: From Mechanisms to Clinical ManagementM Cecilia Bahit, Pilar Agudo-Quilez, Jose Zamorano, et al.
Pharmacoeconomics - Open|June 23, 2025
Cost-Effectiveness of the CADScor System in Low-Risk Patients Presenting to the Emergency Department with Chest PainSuzanne J Baron, Serge Korjian, C Michael Gibson, et al.
Biology Methods & Protocols|May 21, 2026
Weight trajectories after last tirzepatide or semaglutide prescription across a federated health networkKarthik Murugadoss, Gowtham Varma, A J Venkatakrishnan, et al.
The American Journal of Cardiology|April 26, 2003
Meta-analysis of corticosteroid treatment in acute myocardial infarctionGregory R Giugliano, Robert P Giugliano, C Michael Gibson, et al.
American Heart Journal|April 23, 2005
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trialMarc S Sabatine, Carolyn H McCabe, C Michael Gibson, et al.
Pageof 68